Overview

Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3

Status:
Completed

Trial end date:
2013-12-01

Target enrollment:

Participant gender:

Summary

This study is to evaluate the safety, tolerability, and antiviral efficacy of sofosbuvir (SOF) in combination with peginterferon alfa 2a (PEG) and ribavirin (RBV) administered for 12 weeks in participants with chronic genotype 2 or 3 hepatitis C virus (HCV) infection who have previously failed prior treatment with an interferon-based regimen.

Phase:

Phase 2

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Interferon-alpha
Molecular Mechanisms of Pharmacological Action
Peginterferon alfa-2a
Ribavirin
Sofosbuvir